Literature DB >> 2821091

Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure.

M Packer1, W H Lee, P D Kessler, N Medina, M Yushak, S S Gottlieb.   

Abstract

To identify patients with severe chronic heart failure who are at greatest risk of developing functional renal insufficiency during converting enzyme inhibition, creatinine clearance was measured in 59 patients before and after long-term therapy with captopril (39 patients) or enalapril (20 patients), while digitalis and diuretic therapy was kept constant. Creatinine clearance increased or remained constant in 33 of the 59 patients (Group I), but declined in the remaining 26 patients (Group II). The two groups were similar with respect to the cause of heart failure, pretreatment renal function and all pretreatment hemodynamic variables. Patients in Group II, however, had lower values for serum sodium concentration (134.8 +/- 1.0 versus 137.0 +/- 0.6 mmol/liter) and higher values for plasma renin activity (10.6 +/- 3.4 versus 3.0 +/- 0.5 ng/ml per hour), received larger doses of furosemide (108 +/- 11 versus 84 +/- 6 mg/day), were more frequently diabetic (42 versus 15%) and were more frequently treated with enalapril (50 versus 21%) than were patients in Group I (all p less than 0.05). By stepwise logistic analysis, only hyponatremia (or an elevated plasma renin activity) and enalapril therapy independently predicted the decline in creatinine clearance during converting enzyme inhibition. These observations could not be explained by changes in systemic blood pressure. In patients with a normal serum sodium concentration (greater than or equal to 137 mmol/liter), creatinine clearance increased with captopril (+21%, p less than 0.05), but not with enalapril (-6%, p = NS).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821091     DOI: 10.1016/s0735-1097(87)80278-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure.

Authors:  G A Riegger; H Kahles; A Wagner; E P Kromer; D Elsner; K Kochsiek
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

2.  Prediction of renal impairment in elderly patients with congestive heart failure treated with captopril.

Authors:  D Schwartz; R Kornowski; I F Schwartz; I Dotan; B Weinreb; M Averbuch; Y Golan; Y Levo; A Iaina
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

4.  Region-specific changes in transient receptor potential vanilloid channel expression in the vasopressin magnocellular system in hepatic cirrhosis-induced hyponatraemia.

Authors:  T P Nedungadi; F R Carreño; J D Walch; C S Bathina; J T Cunningham
Journal:  J Neuroendocrinol       Date:  2012-04       Impact factor: 3.627

Review 5.  Medical management of congestive heart failure.

Authors:  A E Arai; B H Greenberg
Journal:  West J Med       Date:  1990-10

6.  Congestive heart failure and converting enzyme inhibition: failure of current prognostic criteria for predicting subsequent renal insufficiency.

Authors:  J Odum; P Carson; G Russell
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

7.  Effects of captopril and enalapril on renal function in elderly patients with chronic heart failure.

Authors:  C A Haffner; M J Kendall; A D Struthers; A Bridges; D J Stott
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

8.  Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease.

Authors:  Ali Ahmed; Michael W Rich; Michael Zile; Paul W Sanders; Kanan Patel; Yan Zhang; Inmaculada B Aban; Thomas E Love; Gregg C Fonarow; Wilbert S Aronow; Richard M Allman
Journal:  Am J Med       Date:  2013-02       Impact factor: 4.965

Review 9.  Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.

Authors:  R C Parish; L J Miller
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

Review 10.  Hyponatremia in patients with heart failure.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.